TFF Pharmaceuticals, Inc. (TFFP)
| Market Cap | 6.59M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | -19.39M |
| Shares Out | 3.47M |
| EPS (ttm) | -7.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,029 |
| Open | 1.930 |
| Previous Close | 1.970 |
| Day's Range | 1.818 - 2.030 |
| 52-Week Range | 1.350 - 11.000 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+2,215.79%) |
| Earnings Date | Nov 12, 2024 |
About TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus ... [Read more]
Financial Performance
In 2023, TFF Pharmaceuticals's revenue was $733,871, an increase of 48.02% compared to the previous year's $495,805. Losses were -$21.24 million, -33.13% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TFFP stock is "Strong Buy" and the 12-month stock price forecast is $44.0.
News
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution conditions FORT WORTH, Texas, Sept. 11, 2024 (GLOB...
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood lev...
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inno...
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary Thin Film Freezing Technology
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing a...
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety E...
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lu...
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing a...
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing...
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-t...
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inn...
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (I
Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC Oral Presentation to Present Updated Data from Phase 2 Tria...
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing...
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and co...
TFF Pharmaceuticals Announces Update on Clinical Programs
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and S...
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
Presentation will feature initial data from the Company's ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC), which is being developed to prevent lung transplant rejection Presentation wi...
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause morta...
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET
TFF Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023 Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...